FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation
FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation
复制标题
DOI：
10.1097/00003072-200303000-00005
复制
发表时间：
2003-03-01
影响因子：
10.6
通讯作者：
Zhuang, HM
中科院分区：
文献类型：
--
作者：
Anderson, GS;Brinkmann, F;Zhuang, HM
目的：射频热消融（RFA）是治疗局灶性肝脏肿瘤的一项新兴技术。磁共振成像（MRI）和计算机断层扫描（CT）目前用于监测RFA后肝脏肿瘤的残留和复发。氟脱氧葡萄糖（FDG）正电子发射断层扫描（PET）是检测肝转移的一种极好的成像方法，但它在RFA治疗的肝肿瘤监测中作为解剖成像的替代方法尚未得到充分的评估。本研究的目的是确定FDG-PET成像在RFA治疗的肝脏肿瘤监测中的作用。方法：回顾性分析13例经RFA治疗的肝脏恶性肿瘤患者，治疗后行FDG-PET扫描。1例患者进行了两次rfa后FDG-PET扫描，8例患者同时进行了MRI扫描，6例患者同时进行了CT扫描。将影像学表现与临床随访结果进行比较。结果：11例患者中有消融部位肿瘤复发（8例）或新转移（3例）。FDG-PET识别了所有11例病例，没有误诊任何病例。在接受MRI扫描的7例PET阳性患者中，3例MRI也呈阳性（42.9%）；其他四个病例要么阴性，要么模棱两可。在接受CT扫描的4例PET阳性患者中，只有2例CT扫描阳性（50%）。所有经PET诊断的复发均经临床随访证实。结论：在本初步研究中，FDG-PET对RFA治疗的肝恶性肿瘤的监测优于解剖成像。
Purpose: Radiofrequency thermal ablation (RFA) is an emerging technique in the treatment of focal hepatic tumors. Magnetic resonance imaging (MRI) and computed tomography (CT) are currently used to monitor hepatic tumors after RFA for residual disease and recurrence. Fluorodeoxyglucose (FDG) positron emission tomography (PET) is an excellent imaging method for the detection of liver metastases, but it has not been thoroughly evaluated as an alternative to anatomic imaging in the surveillance of liver tumors treated with RFA. The purpose of this investigation was to determine the role of FDG-PET imaging in the surveillance of liver tumors treated with RFA.Methods: Thirteen patients with histories of malignant tumors of the liver treated with RFA and who had received post-treatment FDG-PET scans were assessed retrospectively. One patient had two post-RFA FDG-PET scans, eight patients had concurrent MRI scans, and six patients had concurrent CT scans. Imaging findings were compared with the results of clinical follow-up.Results: There were either recurrent tumors at the ablation site (8 patients) or new metastases (3 patients) in 11 patients. FDG-PET identified all 11 cases and did not misidentify any cases. Of the seven patients with positive PET findings who received an MRI scan, three were also positive on MRI (42.9%); the other four cases were either negative or equivocal. Of the four patients with positive PET findings who received a CT scan, only two had positive CT scan findings (50%). All recurrences diagnosed by PET were confirmed on clinical follow-up.Conclusion: In this preliminary study, FDG-PET was superior to anatomic imaging in the surveillance of patients treated with RFA for malignant hepatic tumors.